Literature DB >> 26332050

Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer.

Massimo Valerio1,2,3, Chukwuemeka Anele1,2, Susan C Charman4, Jan van der Meulen4, Alex Freeman5, Charles Jameson5, Paras B Singh6, Mark Emberton1,2, Hashim U Ahmed1,2.   

Abstract

OBJECTIVES: To determine whether modified transperineal template prostate-mapping (TTPM) biopsy protocols, altering the template or the biopsy density, have sensitivity and negative predictive value (NPV) equal to full 5-mm TTPM. PATIENTS AND METHODS: Retrospective analysis of an institutional registry including treatment-naïve men undergoing 5-mm TTPM biopsy analysed in a 20-zone fashion. The value of three modified strategies was assessed by comparing the information provided by selected zones against full 5-mm TTPM. Strategy 1, did not consider the findings of anterior areas; strategies 2 and 3 simulated a reduced biopsy density by excluding intervening zones. A bootstrapping technique was used to calculate reliable estimates of sensitivity and NPV of these three strategies for the detection of clinically significant disease (maximum cancer core length ≥4 mm and/or Gleason score ≥3 + 4).
RESULTS: In all, 391 men with a median (interquartile range, IQR) age of 62 (58-67) years were included. The median (IQR) PSA level and PSA density were 6.9 (4.8-10) ng/mL and 0.17 (IQR 0.12-0.25) ng/mL/mL, respectively. A median (IQR) of 6 (2-9) cores out of 48 (33-63) taken per man were positive for prostate cancer. No cancer was detected in 67 men (17%), whilst low-, intermediate- and high-risk disease was identified in 78 (20%), 80 (21%), and 166 (42%), respectively. Strategy 1, 2 and 3 had sensitivities of 78% [95% confidence interval (CI) 73-84%], 85% (95% CI 80-90%) and 84% (95% CI 79-89%), respectively. The NPVs of the three strategies were 73% (95% CI 67-80%), 80% (95% CI 74-86%) and 79% (95% CI 72-84%), respectively.
CONCLUSION: Altering the template or decreasing sampling density has a substantial negative impact on the ability of TTPM biopsy to exclude clinically significant disease. This should be considered when modified TTPM biopsy strategies are used to select men for tissue-preserving approaches, and when modified TTPM are used to validate new diagnostic tests.
© 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biopsy; prostate neoplasms; template-mapping biopsy

Mesh:

Year:  2015        PMID: 26332050     DOI: 10.1111/bju.13306

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP).

Authors:  Solene-Florence Kammerer-Jacquet; Eva Compérat; Lars Egevad; Ondra Hes; Jon Oxley; Murali Varma; Glen Kristiansen; Daniel M Berney
Journal:  Virchows Arch       Date:  2018-01-11       Impact factor: 4.064

Review 2.  Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review.

Authors:  D A Smit Duijzentkunst; M Peters; J R N van der Voort van Zyp; M A Moerland; M van Vulpen
Journal:  World J Urol       Date:  2016-03-24       Impact factor: 4.226

3.  Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies.

Authors:  Nissar Sheikh; Cheng Wei; Magdalena Szewczyk-Bieda; Annie Campbell; Shaukat Memon; Stephen Lang; Ghulam Nabi
Journal:  World J Urol       Date:  2016-05-28       Impact factor: 4.226

4.  Outcomes of combination MRI-targeted and transperineal template biopsy in restaging low-risk prostate cancer for active surveillance.

Authors:  Kenneth Chen; Kae Jack Tay; Yan Mee Law; Hakan Aydin; Henry Ho; Christopher Cheng; John Shyi Peng Yuen
Journal:  Asian J Urol       Date:  2017-07-12

5.  Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI.

Authors:  Maudy C W Gayet; Anouk A M A van der Aa; Harrie P Beerlage; Bart Ph Schrier; Maaike Gielens; Roel Heesakkers; Gerrit J Jager; Peter F A Mulders; Hessel Wijkstra
Journal:  Prostate Cancer       Date:  2020-04-03

6.  Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis.

Authors:  Pranav Satish; Alex Freeman; Daniel Kelly; Alex Kirkham; Clement Orczyk; Benjamin S Simpson; Francesco Giganti; Hayley C Whitaker; Mark Emberton; Joseph M Norris
Journal:  BMJ Open       Date:  2022-01-05       Impact factor: 2.692

7.  Histopathology: ditch the slides, because digital and 3D are on show.

Authors:  Ilaria Jansen; Marit Lucas; C Dilara Savci-Heijink; Sybren L Meijer; Henk A Marquering; Daniel M de Bruin; Patricia J Zondervan
Journal:  World J Urol       Date:  2018-02-02       Impact factor: 4.226

Review 8.  Current techniques of prostate biopsy: an update from past to present.

Authors:  Mohamed Essam Noureldin; Martin J Connor; Nicholas Boxall; Saiful Miah; Taimur Shah; Jochen Walz
Journal:  Transl Androl Urol       Date:  2020-06

9.  Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT).

Authors:  E J Alexander; J R Murray; V A Morgan; S L Giles; S F Riches; S Hazell; K Thomas; S A Sohaib; A Thompson; A Gao; D P Dearnaley; N M DeSouza
Journal:  Radiother Oncol       Date:  2019-09-05       Impact factor: 6.280

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.